Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antiviral therapy found to prevent blindness, other serious effects for patients with eye shingles

11.03.2003


Mayo Clinic has found that for patients with eye shingles, oral antiviral drugs are critical to prevent long-term consequences in the eye. Untreated, 10 percent of eye shingles patients experience a serious long-term outcome, such as severe visual loss, eyelid scarring or chronic in-turning of the eyelashes; if treated, two percent of patients experience these effects. The Mayo Clinic study refutes the findings of a previous British study of oral antivirals in patients with eye shingles.



"This is the first time it’s been documented that within the eye, the chance of something really bad happening is greatly reduced by administering oral antivirals," says Keith Baratz, M.D., Mayo Clinic ophthalmologist and author of the manuscript, "Herpes Zoster Ophthalmicus in Olmsted County, Minnesota: Have Systemic Antivirals Made a Difference?" to be published in the March issue of Archives of Ophthalmology, http://archopht.ama-assn.org.

This study, based on data from the Rochester Epidemiology Project, http://www.mayo.edu/research/mir/topic_1029.html, is the first long-term follow-up study and the second largest study of this medication with patients diagnosed with herpes zoster opthalmicus. The largest study completed of oral antivirals for this disease to date, by Moorfield’s Eye Hospital in London, found that oral antivirals did not significantly affect long-term outcome; the study was not well controlled, however, according to the Mayo Clinic researchers. Oral antiviral treatment has been controversial due to the Moorfield’s study as well as the cost of the medicine, which can cost several hundred dollars for a course of treatment, or approximately $13 to $22 per day.


This study compared 323 cases of eye shingles treated in Olmsted County, Minn., between 1976 and 1998. Of these cases, two-thirds, or 202 patients, were treated with oral antiviral medication, such as acyclovir, famciclovir or valacyclovir; and one-third, or 121, were not treated. In untreated patients, 8.9 percent experienced adverse outcomes five to 10 years following the onset of the illness; 2.1 percent of treated patients experienced such outcomes. Also, the group given oral antivirals was less likely to experience the complication neurotrophic keratitis, or loss of feeling in and inflammation of the cornea. Those treated, however, did experience more frequent conjunctivitis, or inflammation of the eyelid-lining membrane and sclera surface, for reasons unknown to the investigators.

Timing of treatment also affected the long-term outcome. Those who experienced long-term negative outcomes such as glaucoma, scleritis (inflammation of the white coating around the eyeball), uveitis (inflammation of the vascular middle coating of the eye), corneal edema or stromal keratitis had waited an average of 4.8 days before receiving treatment; those who did not experience these outcomes waited an average of 3.8 days prior to treatment.

"A delay in treatment with the drug negatively affected the course of the disease," says Dr. Baratz. "Getting in to your doctor quickly is an issue."

According to Dr. Baratz, receiving timely treatment for eye shingles is complicated, however, by nonspecific symptoms at the start of the disease. The origin of these early symptoms also is difficult to pinpoint.

"You can get headaches first, or a rash first or pinkeye first," says Dr. Baratz. "Very early on it can be difficult to diagnose." He adds, however, that herpes zoster ophthalmicus is very easy to diagnose once the rash starts.

Herpes zoster, or shingles, is a common condition; 20 percent of all those who have had chicken pox will get shingles, and 20 percent of those experience the disease in the eye. People at higher risk for the disease include the elderly, patients taking immunosuppressant drugs or those experiencing high stress. It may strike people of any age. The virus causing the disease, varicella zoster, can remain in the body and lie "dormant," reactivating years later in nerve cells. Factors such as stress, medications, illness and aging may prompt the reactivation.

"You can get chicken pox when you’re three years old, and it can come back when you’re 70," says Dr. Baratz. " Everyone who has shingles has had chicken pox before. Chicken pox usually is not a big deal; shingles is a big deal."

Herpes zoster most commonly occurs in the body’s trunk, but it also may spread along the ophthalmic portion of the fifth cranial nerve, affecting the eye. The symptoms manifest in one eye only, as shingles typically concentrate on one side of the body.

"It is very painful and can destroy your sight," says Dr. Baratz.

Lisa Copeland | EurekAlert!
Further information:
http://www.mayo.edu/research/mir/topic_1029.html

More articles from Health and Medicine:

nachricht Minimising risks of transplants
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

nachricht FAU researchers demonstrate that an oxygen sensor in the body reduces inflammation
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Stiffness matters

22.02.2018 | Life Sciences

Magnetic field traces gas and dust swirling around supermassive black hole

22.02.2018 | Physics and Astronomy

First evidence of surprising ocean warming around Galápagos corals

22.02.2018 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>